Patrys Limited (AU:PAB) has released an update.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Patrys Limited has bolstered its financial standing by receiving a $1.285 million rebate through the Australian Government’s R&D Tax Incentive scheme. This refund supports the ongoing development of their innovative deoxymab platform, which targets cancer cells and inflammatory diseases. The company’s commitment to advancing these therapies could potentially revolutionize cancer treatment options.
For further insights into AU:PAB stock, check out TipRanks’ Stock Analysis page.
